Resistance of gonadotropin releasing hormone drive to sex steroid- induced suppression in hyperandrogenic anovulation

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 12, 1997, Pages 4179-4183

  Daniels, Tammy L ^a   Berga, Sarah L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; ESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE; FOLLITROPIN; GONADORELIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; TESTOSTERONE;

ADULT; ANOVULATION; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERANDROGENISM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; LUTEINIZING HORMONE RELEASE; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULSATILE HORMONE RELEASE; STEROID BLOOD LEVEL;

EID: 0030735282     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.12.4179     Document Type: Article

References (32)

1. Berga SL, Guzick DS, Winters SDI. 1993 Increased LH, and α-subunit secretion in women with hyperandrogenic anovulation. J Clin Endocrinol Metab. 77:895-901.
2. Kazer RR, Kessel B, Yen SSC. 1987 Circulating luteinizing hormone pulse frequency in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 65:233-236.
3. Waldstreicher J, Santoro NF, Hall JE, Filicori M, Crowley Jr WF. 1988 Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab. 66:165-172.
4. Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SSC. 1996 Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab. 81:2854-2864.
5. Berga SL, Yen SCC. 1989 Opioidergic regulation of LH pulsatility in women with polycystic syndrome. Clin Endocrinol (Oxf). 30:177-184.
6. Spratt DI, Finkelstein JS, Butler JP, Badger TM, Crowley Jr WR. 1987 Effects of increasing frequency of low doses of GnRH on gonadotropin secretion in GnRH-deficient men. J Clin Endocrinol Metab. 64:1179-1186.
7. Gross KM, Matsumoto AM, Bremner WJ. 1987 Differential control of LH and FSH secretion by LHRH pulse frequency in man. J Clin Endocrinol Metab. 64:675-680.
8. Yen SSC, Vela P, Rankin J. 1970 Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab. 30:435-442.
9. Hemrika DJ, Slaats EH, Kennedy JC, DeVries Robles-Korsen TJM, Schoemaker J. 1993 Pulsatile luteinizing hormone patterns in long term oral contraceptive users. J Clin Endocrinol Metab. 77:420-426.
10. Dewailly D, Vantyghem-Haudiquet M-C, Sainsard C, et al. 1986 Clinical and biological phenotypes in late-onset 21 hydroxylase deficiency. J Clin Endocrinol Metab. 63:418-423.
11. Veldhuis JD, Johnson ML. 1986 Cluster analysis: a simple, versatile, and robust algorithm for endocrine pulse detection. Am J Physiol. 250:E486-E493.
12. Christman GM, Randolph JF, Kelch RP, Marshall JC. 1991 Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease. J Clin Endocrinol Metab. 72:1278-1285.
13. Soules MR, Clifton DK, Bremner WJ, Steiner RA. 1987 Corpus luteum insufficiency induced by a rapid gonadotropin-releasing hormone-induced gonadotropin secretion pattern in the follicular phase. J Clin Endocrinol Metab. 65:457-464.
14. Cumming DC, Reid RL, Quigley ME, Rebar RW, Yen SSC. 1984 Evidence for decreased endogenous dopamine and opioid inhibitory influences on LH secretion in polycystic ovary syndrome. Clin Endocrinol (Oxf). 20:643-648.
15. Buvat J, Buvat-Herbaut M, Marcolin G, et al. 1986 A double blind controlled study of the hormonal and clinical effects of bromocriptine in the polycystic ovary syndrome. J Clin Endocrinol Metab. 63:119-124.
16. Steingold KA, Lobo RA, Judd HL, Lu JHL, Chang RJ. 1986 The effect of bromocriptine on gonadotropin and steroid secretion in polycystic ovarian disease. J Clin Endocrinol Metab. 62:1048-1051.
17. Rosen GF, Lobo RA. 1987 Further evidence against dopamine deficiency as the cause of inappropriate gonadotropin secretion in patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 65:891-895.
18. Barnes RB, Mileikowsky GN, Cha KW, Spencer CA, Lobo RA. 1986 Effects of dopamine and metoclopramide in polycystic ovary syndrome. J Clin Endocrinol Metab. 63:506-509.
19. Guzick DS, Wing R, Smith D, Berga SL, Winters SJ. 1994 Endocrine consequences of weight loss in obese, hyperandrogenic anovulatory women. Fertil Steril. 61:598-604.
20. Nestler JE, Barlascini CO, Matt DW, et al. 1989 Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 68:1027-1032.
21. Ehrmann DA, Cavaghan MK, Imperial J, Sturgis J, Rosenfield RL, Polonsky KS. 1997 Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:524-530.
22. Ehrmann DA, Schneider DJ, Sobel BE, et al. 1997 Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:2108-2116.
23. Dunaif A, Graf M. 1989 Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with polycystic ovary syndrome. J Clin Invest. 83:23-29.
24. Velazquez EM, Mendoza SG, Wang P, Glucek CJ. 1997 Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism. 46:454-457.
25. Nestler JE, Jakubowicz DJ. 1996 Decreases in cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 335:617-623.
26. Plant TM. 1986 A striking sex difference in the gonadotropin response to gonadectomy during infantile development in the rhesus monkey (Macaca mulatta). Endocrinology. 119:539-545.
27. Ammini AC, Pandey J, Vijyaraghavan M, Sabherwal U. 1994 Human female development: role of fetal ovaries. J Clin Endocrinol Metab. 79:604-608.
28. Barnes RB, Rosenfield RL, Ehrmann DA, et al. 1994 Ovarian hyperandrogenism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab. 79:1328-1333.
29. Levin JH, Carmina E, Lobo RA. 1991 Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia? Fertil Steril. 56:635-640.
30. Ruchhoft EA, Elkind-Hirsch KE, Malinak R. 1996 Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist. Fertil Steril. 66:54-60.
31. Korytkowski MT, Mokan M, Horwitz MJ, Berga SL. 1995 Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 80:3327-3334.
32. Talbott E, Guzick D, Clerici A, et al. 1995 Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol. 15:821-826.